Full-Time
Regional Hematology Manager
Minnesota
Posted on 7/1/2025
Omeros
201-500 employees
Biopharmaceutical company developing MASP-2 inhibitors
No salary listed
North Dakota, USA + 2 more
More locations: South Dakota, USA | Minnesota, USA
Remote
 Sales & Account Management (3) |
|---|
| , , |
- Bachelor’s degree is required, with a concentration in the life sciences or healthcare field preferred; MBA or an advanced degree is preferred
- 10 years of sales experience in the pharmaceutical industry, with a minimum of 5 years of rare disease or orphan disease territory management experience; experience in hematology and especially HSCT is also a plus
- Launch experience is required
- Specialty experience is required, oncology and hematology experience preferred
- Experience working with major Blood and Marrow Transplant Centers and the key opinion leaders within those centers
- Must have the ability to drive to or fly to various meetings/client sites
- Overnight and weekend travel is required and may vary depending on individual territory size, customer locations and business needs; exact amount of travel required is based on territory customer locations
- Must reside in assigned territory
- Must have a valid driver’s license and an acceptable driving record
- Documented, consistent, above-average performance in prior sales positions
- Experience in and knowledge of Microsoft applications as well as Veeva CRM in order to track call activity and sales progress
- Maintain Company and Industry Compliance Rules
- You will be expected to work remotely from your assigned region
- Responsible for managing the business within a specific geographical territory area
- Responsible for disease state awareness materials and educating customers on the signs and symptoms of thrombotic microangiopathy (TMA) as it relates to HSCT patients in their targeted institutions
- Participate in and help create pre-launch strategies that will be used to ensure a successful launch of a product currently under review by the FDA for the treatment of HSCT-TMA
- Pending FDA approval, this individual will be responsible for educating customers on a monoclonal antibody used to treat HSCT-TMA in targeted hospitals that are located across the assigned territory with a focus on the following departments: HSCT physicians, hematologists, nephrologists, nurses, and pharmacists
- Some responsibilities as it relates to the reimbursement and access of the product and will call on Pharmacy directors, social workers and others related to ensuring the access and distribution of the product
- Execute on the National sales and marketing strategy and create a territory business plan to maximize opportunity
- Work in partnership with home office personnel, the Brand team and the National and Corporate account teams for pull-through of product sales
- Responsible for running the business by analyzing account and physician sales data and creating territory tactical plans and providing solutions to grow the business
- Experience in and knowledge of Microsoft applications as well as Veeva CRM in order to track call activity and sales progress
- Maintain Company and Industry Compliance Rules
- Possess in-depth knowledge of the medical industry
- Familiarity with adding products to Hospital Formularies
- Knowledge of products used in the HSCT arena (Chemotherapy, radiation, supportive care products) is preferred
- Documented, consistent, above-average performance in prior sales positions
- Strong organizational skills and ability to manage multiple tasks/priorities
- Above average proficiency with basic technology tools (e.g. Microsoft Office products, Veeva CRM, etc.)
- Demonstrated ability to build and maintain positive relationships with management, peers, and subordinates
- Integrity
Omeros develops therapeutics that target the immune system, focusing on complement pathway biology to treat immunologic and CNS disorders. It manages the full drug process from discovery to commercialization through a vertically integrated model. The lead candidate narsoplimab blocks MASP-2 in the lectin pathway to reduce inflammation without impairing the classical pathway, with other programs targeting MASP-3 and long-acting MASP-2 inhibitors. The goal is to address unmet medical needs by advancing complement-targeted therapies and expanding its pipeline and collaborations.
Company Size
201-500
Company Stage
IPO
Headquarters
Charlottesville, Virginia
Founded
1994
Simplify's Take
What believers are saying
- Novo Nordisk deal yields $340M upfront plus $2.1B milestones.
- YARTEMLEA ships commercially to 80 high-volume US transplant centers.
- $171.8M cash supports positive cash flow by 2027.
What critics are saying
- EMA delays YARTEMLEA approval past mid-2026, blocking Europe revenue.
- Novo terminates zaltenibart milestones after Phase III PNH failure.
- OMS1029 Phase II fails efficacy, halting MASP-2 pipeline.
What makes Omeros unique
- YARTEMLEA inhibits MASP-2, targeting lectin pathway uniquely.
- First FDA-approved therapy for TA-TMA in adults and pediatrics.
- Vertically integrated from discovery to commercialization since 1994.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%Omeros Corporation reported its Q4 2025 earnings, highlighting its transition to a commercial-stage company following FDA approval of YARTEMLEA, the first treatment for TA-TMA. The company sold zaltenibart to Novo Nordisk for up to $2.1 billion, using proceeds to fully repay senior secured debt. Management expects YARTEMLEA to achieve financial self-sustainability within 2026 and company-wide positive cash flow in 2027. The commercial strategy targets 80 high-volume transplant centres representing 80% of the US market. A European regulatory decision is anticipated by mid-2026. Reported net income included a $136 million non-cash charge on embedded derivatives, driven by a 319% stock price increase in Q4. The company expects $100 million in near-term milestones from Novo Nordisk and is advancing its MASP-2 pipeline, including Phase II candidate OMS1029.
Omeros Corp has reported a net income of $86.5 million for Q4 2025, reversing a $30.9 million loss in the previous quarter, driven by a $237.6 million gain from its zaltnibart transaction with Novo Nordisk. The company closed an asset purchase and license deal with Novo Nordisk valued at up to $2.1 billion, including a $240 million upfront payment. This helped strengthen Omeros's balance sheet, with cash and investments reaching $171.8 million as of 31st December 2025. The FDA approved YARTEMLEA, the first treatment for TA-TMA, priced at approximately $36,000 per vial. The company has begun early sales deployment but has not provided revenue guidance due to the launch's early stage. Omeros has reduced outstanding debt to $70.8 million in convertible notes.
Omeros announces upcoming presentation at EBMT 2026 highlighting advances in TA-TMA Treatment. * 2 hrs ago Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled "Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy," will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children's Healthcare of Atlanta. The EBMT Annual Meeting is a key event for professionals in transplantation and cellular therapy, bringing together stakeholders from around the world. About Omeros Corporation Omeros is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead lectin pathway inhibitor YARTEMLEA(R)(narsoplimab-wuug), which inhibits the pathway's effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros' pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder that is fully funded by the National Institute on Drug Abuse, as well as a growing portfolio of novel molecular and cellular oncology programs. For more information about Omeros and its programs, visit www.omeros.com.
Omeros Corporation has completed its first commercial shipments of YARTEMLEA (narsoplimab-wuug), with transplant centres beginning orders immediately. Both adult and paediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving treatment in hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for TA-TMA, a potentially fatal complication of stem cell transplantation. The drug received FDA approval on 23 December 2025 for use in adults and children aged two years and older. TA-TMA develops in up to 56% of allogeneic transplant recipients, according to recent studies. Approximately 30,000 allogeneic transplants are performed annually in the United States and Europe. A marketing authorisation application is under review by the European Medicines Agency, with a decision expected in mid-2026.
Novo Nordisk snaps up Omeros' rare disease asset for up to $2.1bn. Novo Nordisk will now run a Phase III trial for zaltenibart in the rare blood disorder, PNH. Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset, zaltenibart. By selling the rights to the monoclonal antibody (mAb), which demonstrated potential in a Phase II trial in blood disorder paroxysmal nocturnal haemoglobinuria (PNH), Omeros will pocket $340m in upfront and short-term milestone payments. The biopharma is also eligible to receive up to $2.1bn in development and commercial milestone payments from Novo Nordisk, depending on how the drug performs in upcoming Phase III trials in PNH. These studies will be initiated and funded by Novo Nordisk. Formerly known as OMS906, zaltenibart was due to enter Phase III clinical trials under Omeros' name, but the company later pressed pause on the drug's late-stage development. This came after Omeros forecasted a "ramp up in spending" on these studies, which led the biopharma to "prioritise" the use of capital currently available to it. Zaltenibart's financial performance could bode well for the rest of Omeros' pipeline, according to investor reaction. The company's stock value shot up more than 180% after the news debuted, going from $4.10 at market close on 14 October to $11.59 at market open on 15 October. Novo's choice to purchase zaltenibart will bolster the company's rare blood disease pipeline, which currently includes five drugs in Phases I to III. This includes erythrocyte pyruvate kinase (PKR) activator etavopivat, which the pharma obtained through its acquisition of Forma in 2022 and is now in Phase III trials for sickle cell disease. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Zaltenibart's future potential. Zaltenibart works by inhibiting the mannan-binding lectin-associated serine protease-3 (MASP-3), a complement system enzyme that is key to activating the alternative pathway. According to Sir Peter Lachmann, Emeritus Sheila Joan Smith Professor of Immunology at the University of Cambridge, MASP-3 inhibitors such as zaltenibart could have "important advantages relative to a complement 5 (C5) inhibitor," for treating PNH. Lachmann noted that this was likely due to zaltenibart's ability to block both intra- and extravascular haemolysis, which he said C5 inhibitors cannot achieve. As a result, zaltenibart could take a chunk of the PNH market if approved. The indication is currently dominated by C5 inhibitors such as AstraZeneca's Soliris (eculizumab) and Ultomiris (ravulizumab). However, the recent market debut of Novartis' Fabhalta (iptacopan) could be a spanner in the works for intravenous (IV) therapies like zaltenibart, as the drug is orally administered - enhancing patient convenience. Outside of PNH, Omeros has previously touted the potential of the mAb in other rare blood and kidney disorders. Following its acquisition of zaltenibart, Novo Nordisk will explore further development opportunities for the drug in a "range" of undisclosed indications. Give your business an edge with our leading industry insights. Pharmaceutical Technology Excellence Awards - The benefits of entering. Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don't miss your chance to stand out - submit your entry today!